New hope for advanced cervical cancer: drug trial targets remaining risk

NCT ID NCT06943833

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called volrustomig in 37 women with high-risk, locally advanced cervical cancer that hasn't gotten worse after standard chemotherapy and radiation. The goal is to see if the drug can help keep the cancer from coming back or spreading. Participants receive the drug by infusion, and researchers track cancer progression and survival over several years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED CERVICAL CANCER

Contacts and locations

Locations

Research Site

Arkhangelsk, 163045, Russia
Research Site

Krasnoyarsk, 660133, Russia
Research Site

Moscow, 111123, Russia
Research Site

Moscow, 115478, Russia
Research Site

Moscow, 115533, Russia
Research Site

Moscow, 117997, Russia
Research Site

Moscow, 125284, Russia
Research Site

Moscow, 125367, Russia
Research Site

Saint Petersburg, 194291, Russia
Research Site

Saint Petersburg, 197758, Russia
Research Site

Ufa, 450054, Russia
Research Site

Yekaterinburg, 620036, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.